Table 3.
Joint effect of number of IPI cycles and best overall response on the proportion of MM patients with elevated (> 200 pg/ml) sCTLA-4 serum levels
| Factors and levels | sCTLA-4 levels > 200 pg/ml vs ≤ 200 pg/ml | p value | |
|---|---|---|---|
| OR | 95%CL | ||
| Number of IPI cycles | |||
| 1 | 1.00 | (Ref.) | 0.016 |
| 2 | 1.57 | 0.95–2.62 | |
| ≥ 3 | 4.41 | 1.02–19.1 | |
| Best overall response | |||
| irCR + irPR | 1.00 | (Ref.) | 0.034 |
| irSD | 0.32 | 0.06–1.73 | |
| irPD | 0.17 | 0.04–0.68 | |
The association between the number of IPI cycles and BOR with sCTLA-4 serum levels (sCTLA-4 > 200 pg/ml vs sCTLA-4 ≤ 200 pg/ml) was estimated through a random-intercept binomial logistic regression modelling. Each OR represents the ratio between the proportion of patients with sCTLA-4 > 200 in a specific category and the same proportion in the reference category
IPI ipilimumab, irCR immune-related complete response, irPR immune-related partial response, irSD immune-related stable disease, irPD immune-related progressive disease, OR odds ratio adjusted for age, gender, time from diagnosis, LDH levels, dNLR, pre-IPI immunotherapy, brain, liver and cutaneous metastases, and participating center, 95%CL 95% confidence limit for OR, p value significance level of the likelihood ratio test for linear trend, Ref reference category